Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
Homma T, Nagata N, Hashimoto M, Iwata-Yoshikawa N, Seki NM, Shiwa-Sudo N, Ainai A, Dohi K, Nikaido E, Mukai A, Ukai Y, Nakagawa T, Shimo Y, Maeda H, Shirai S, Aoki M, Sonoyama T, Sato M, Fumoto M, Nagira M, Nakata F, Hashiguchi T, Suzuki T, Omoto S, Hasegawa H. Homma T, et al. Among authors: shiwa sudo n. Sci Rep. 2022 Dec 2;12(1):20861. doi: 10.1038/s41598-022-25418-5. Sci Rep. 2022. PMID: 36460696 Free PMC article.
Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways.
Iwata-Yoshikawa N, Kakizaki M, Shiwa-Sudo N, Okura T, Tahara M, Fukushi S, Maeda K, Kawase M, Asanuma H, Tomita Y, Takayama I, Matsuyama S, Shirato K, Suzuki T, Nagata N, Takeda M. Iwata-Yoshikawa N, et al. Among authors: shiwa sudo n. Nat Commun. 2022 Oct 15;13(1):6100. doi: 10.1038/s41467-022-33911-8. Nat Commun. 2022. PMID: 36243815 Free PMC article.
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, Yoshihara K, Iwata-Yoshikawa N, Shiwa-Sudo N, Sakai Y, Shirakura M, Kishida N, Arita T, Suzuki Y, Watanabe S, Asanuma H, Sonoyama T, Suzuki T, Omoto S, Hasegawa H. Hashimoto M, et al. Among authors: shiwa sudo n. Vaccine. 2022 Jul 29;40(31):4231-4241. doi: 10.1016/j.vaccine.2022.05.081. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35691872 Free PMC article.
Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
Shiwa-Sudo N, Sakai Y, Iwata-Yoshikawa N, Watanabe S, Yamada S, Kuroda Y, Yamamoto T, Shirakura M, Fujisaki S, Miyazaki K, Miura H, Nagata S, Fukushi S, Maeda K, Hasegawa H, Suzuki T, Nagata N. Shiwa-Sudo N, et al. J Virol. 2023 Jan 31;97(1):e0136622. doi: 10.1128/jvi.01366-22. Epub 2023 Jan 12. J Virol. 2023. PMID: 36633406 Free PMC article.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: shiwa sudo n. Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4. Med. 2022. PMID: 35261995 Free PMC article.
Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults.
Morino E, Mine S, Tomita N, Uemura Y, Shimizu Y, Saito S, Suzuki T, Okumura N, Iwasaki H, Terada J, Ainai A, Sakai Y, Park E, Seki S, Akazawa D, Shimojima M, Shiwa-Sudo N, Virhuez-Mendoza M, Miyauchi K, Moriyama S, Iwata-Yoshikawa N, Harada M, Harada S, Hishiki T, Kotaki R, Matsumura T, Miyamoto S, Kanno T, Isogawa M, Watashi K, Nagata N, Ebihara H, Takahashi Y, Maeda K, Matano T, Wakita T, Suzuki T, Sugiura W, Ohmagari N, Ujiie M. Morino E, et al. Among authors: shiwa sudo n. NEJM Evid. 2024 Mar;3(3):EVIDoa2300290. doi: 10.1056/EVIDoa2300290. Epub 2024 Feb 27. NEJM Evid. 2024. PMID: 38411447
Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval.
Miyamoto S, Kuroda Y, Kanno T, Ueno A, Shiwa-Sudo N, Iwata-Yoshikawa N, Sakai Y, Nagata N, Arashiro T, Ainai A, Moriyama S, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Fukushi S, Takahashi Y, Maeda K, Suzuki T. Miyamoto S, et al. Among authors: shiwa sudo n. iScience. 2023 May 19;26(5):106694. doi: 10.1016/j.isci.2023.106694. Epub 2023 Apr 19. iScience. 2023. PMID: 37124417 Free PMC article.
Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Ueno M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, Saito S, Ashida S, Yoshida I, Nagashima M, Asakura H, Yaoita Y, Suzuki J, Sadamasu K, Yoshimura K, Kutsuna S, Shiwa-Sudo N, Nagata N, Suzuki T, Suzuki A, Okamoto M, Kimura M, Ohmagari N, Miura R, Ishizaka Y. Ueno M, et al. Among authors: shiwa sudo n. Antiviral Res. 2022 May;201:105297. doi: 10.1016/j.antiviral.2022.105297. Epub 2022 Mar 24. Antiviral Res. 2022. PMID: 35341809 Free PMC article.
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T, Ainai A, Hashiguchi T, Tobiume M, Kanno T, Iwata-Yoshikawa N, Iida S, Sato Y, Miyamoto S, Ueno A, Sano K, Saito S, Shiwa-Sudo N, Nagata N, Tamura K, Suzuki R, Hasegawa H, Suzuki T. Hemmi T, et al. Among authors: shiwa sudo n. Vaccine. 2022 Sep 29;40(41):5892-5903. doi: 10.1016/j.vaccine.2022.08.049. Epub 2022 Aug 26. Vaccine. 2022. PMID: 36064667 Free PMC article.
12 results